David Hallal Biography and Net Worth

Director of AlloVir

David is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies. During his 10-year tenure at Alexion Pharmaceuticals, where he served as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer, he led the pipeline expansion from a single-product to multi-product company, resulting in Alexion’s inclusion into the S&P500. Prior to Alexion, David spent nearly 20 years at Amgen, Biogen, and Eyetech in executive and senior leadership roles.

David also serves as Chairman and CEO of ElevateBio, an Independent Chairman of Scholar Rock (SRRK) and iTeos Therapeutics as well as an Independent Director of Seer. He holds a BA in psychology from the University of New Hampshire.

What is David Hallal's net worth?: The estimated net worth of David Hallal is at least $9.36 million as of January 13th, 2026. Mr. Hallal owns 1,541,645 shares of AlloVir stock worth more than $9,357,785 as of April 10th. This net worth evaluation does not reflect any other investments that Mr. Hallal may own. Learn More about David Hallal's net worth.
How do I contact David Hallal?: The corporate mailing address for Mr. Hallal and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on David Hallal's contact information.
Has David Hallal been buying or selling shares of AlloVir?: David Hallal has not been actively trading shares of AlloVir during the last ninety days. Most recently, David Hallal sold 26,086 shares of the business's stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $194.35, for a transaction totalling $5,069,814.10. Following the completion of the sale, the director now directly owns 6,006 shares of the company's stock, valued at $1,167,266.10. Learn More on David Hallal's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

David Hallal Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/19/2022	Sell	26,086	$194.35	$5,069,814.10	6,006
9/29/2022	Sell	17,391	$169.05	$2,939,948.55	31,346
7/21/2022	Sell	183	$122.59	$22,433.97	90,159
4/21/2022	Sell	183	$135.01	$24,706.83	93,200
3/10/2022	Sell	1,760	$173.65	$305,624.00
1/24/2022	Sell	743	$184.23	$136,882.89

David Hallal Buying and Selling Activity at AlloVir

AlloVir Company Overview

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Today's Range

Now: $6.07

$5.83

$6.64

50 Day Range

MA: $8.36

$5.30

$10.98

2 Week Range

Now: $6.07

$7.96

$24.15

Volume

67,533 shs

Average Volume

15,685 shs

Market Capitalization

$30.61 million

P/E Ratio

N/A

Dividend Yield